Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $54.00 at Jefferies Financial Group

Key Points

• Jefferies Financial Group raised its price target for Kiniksa Pharmaceuticals International from $45.00 to $54.00, indicating a potential upside of **77.81%** from the current price.
• Wells Fargo upgraded its rating to "overweight" with a new price target of **$42.00**, while seven analysts currently rate Kiniksa as a buy.
• Kiniksa Pharmaceuticals reported **$0.23 EPS** for the last quarter, surpassing estimates, though it faces negative net margins and a projected **-0.55 EPS** for the fiscal year.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Free Report) had its price target raised by Jefferies Financial Group from $45.00 to $54.00 in a report published on Tuesday,Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock.

Other research analysts have also issued research reports about the stock. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday, July 6th. Wells Fargo & Company increased their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Finally, Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Kiniksa Pharmaceuticals International has a consensus rating of "Buy" and a consensus target price of $41.17.

Kiniksa Pharmaceuticals International Stock Up 5.7%

Shares of KNSA stock traded up $1.72 on Tuesday, reaching $31.98. 1,072,119 shares of the stock were exchanged, compared to its average volume of 611,693. The stock has a market cap of $2.33 billion, a P/E ratio of 799.70 and a beta of 0.14. The firm has a 50 day moving average of $28.38 and a two-hundred day moving average of $24.07. Kiniksa Pharmaceuticals International has a 1-year low of $17.82 and a 1-year high of $32.15.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. On average, equities research analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 18,900 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $28.72, for a total value of $542,808.00. Following the transaction, the chief operating officer owned 49,163 shares in the company, valued at $1,411,961.36. The trade was a 27.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Barry D. Quart sold 12,336 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $30.39, for a total transaction of $374,891.04. Following the completion of the transaction, the director directly owned 12,546 shares of the company's stock, valued at approximately $381,272.94. The trade was a 49.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 320,981 shares of company stock worth $9,189,467 over the last three months. Insiders own 53.48% of the company's stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently modified their holdings of the business. GAMMA Investing LLC boosted its holdings in Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after purchasing an additional 568 shares during the last quarter. US Bancorp DE purchased a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $33,000. Asset Management One Co. Ltd. purchased a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter valued at approximately $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth approximately $42,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth $61,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.